Let's do that.
WHO:
“Every time one country demands a lower price, it leads to a lower reference price used by other countries. Such price controls, combined with the threat of market lockout or intellectual property infringement, prevent drug companies from charging market rates for their products, while delaying the availability of new cures to patients living in countries implementing these policies.”
This is seen in the data: Of 74 cancer drugs launched between 2011 and 2018, 70 (95%) are available in the United States. Compare that with 74% in the U.K., 49% in Japan, and 8% in Greece.
Scientists at non profit RAND:
According to one estimate, if the U.S. were to adopt European-level price controls, the reductions in U.S. prices today would result in
0.7 years lower longevity for future cohorts of Americans and Europeans due to fewer new drugs. This would cost Americans more than $50,000 per person when the value of foregone health is valued.
As someone living in the US, purely for selfish reasons, I would be all for a collective bargaining/cap. One just has to be cognizant that the academic research indicates this will be at the cost of longer term longevity declines.
This was one of the Trump admin's better ideas but as with all of their good ideas, it never went anywhere.
Health and Human Services has invited comment on a potential rule that would tether what Medicare Part B pays for certain drugs to a price index of what other developed countries pay. The goal is to bring prices down to 126% of what other countries pay, versus 180% today.